{"id":158127,"date":"2026-11-10T08:23:16","date_gmt":"2026-11-10T08:23:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/158127\/"},"modified":"2026-11-10T08:23:16","modified_gmt":"2026-11-10T08:23:16","slug":"acr-2026-novartis-abogens-mrna-t-cell-engager-shows-initial-promise-in-scleroderma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/158127\/","title":{"rendered":"ACR 2026: Novartis\/Abogen\u2019s mRNA T-Cell Engager Shows Initial Promise In Scleroderma"},"content":{"rendered":"<p><a aria-label=\"Scrip home\" class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" height=\"70px\" src=\"https:\/\/insights.citeline.com\/pf\/resources\/images\/sectionsLogo\/scrip.svg?d=172\" alt=\"Scrip logo\"\/><\/a><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\/immunological\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p class=\"c-paragraph b-subheadline-paragraph\">In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.<\/p>\n<p><img decoding=\"async\" data-chromatic=\"ignore\" alt=\"SCLERODERMA Medicine doctor hand working on virtual screen\" class=\"c-image\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/2M6UV3CYJFF6PNGSWUWP7I3H4M.jpg\" width=\"700\" height=\"394\"\/>Scleroderma involves skin hardening and tightening, affecting blood vessels, internal organs and the digestive tract (Shutterstock) <\/p>\n<p class=\"c-paragraph\">Novartis and Chinese partner Abogen Biosciences\u2019 messenger RNA-based T-cell engager has shown distinct differentiation in the clinic from other B-cell-depleting agents for autoimmune disorders, despite preliminary results generated from an investigator-initiated trial (IIT).<\/p>\n<p>Key TakeawaysIn five patients with systemic sclerosis (scleroderma), Novartis\/Abogen&#8217;s ABO2203, a subcutaneous mRNA-lipid nanoparticle, encoding CD19\u00d7CD3 T cell engager, caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, without steroid premedication.<\/p>\n<p class=\"c-paragraph\">The initial findings are expected to help speed up the upcoming company-sponsored studies of ABO2203, which Novartis acquired from Abogen&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated&hellip;\n","protected":false},"author":2,"featured_media":158128,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[67248,67121,73934,73932,73935,206,36658,73933],"class_list":["post-158127","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-abo2203","tag-abogen","tag-american-college-of-rheumatology","tag-autoimmune-disease-research","tag-mrna-t-cell-engager","tag-novartis","tag-systemic-sclerosis","tag-systemic-sclerosis-treatment"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117591185921549732","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/158127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=158127"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/158127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/158128"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=158127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=158127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=158127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}